Document is current
Any future updates will be listed below
-
Authors
Rautakorpi, Jaakko https://orcid.org/0000-0003-4361-6764
Kolehmainen, Sara https://orcid.org/0009-0003-5176-9709
Löyttyniemi, Eliisa https://orcid.org/0000-0002-7278-6511
Björkesten, Clas-Göran af https://orcid.org/0000-0003-3406-8612
Arkkila, Perttu https://orcid.org/0000-0003-2194-0424
Sipponen, Taina https://orcid.org/0000-0002-8069-5273
Salminen, Kimmo https://orcid.org/0000-0001-5518-9240
-
Funding
Funding for this research was provided by:
University of Turku
- License Information
-
More Information
Article History
Received: 26 November 2024
Accepted: 15 January 2025
First Online: 13 February 2025
Declarations
:
: J.R. has received support from Abbvie, Pfizer, and Takeda for meeting attendance and travel expenses and has participated in planning educational meetings for Abbvie. C.G.B. has received speaker and consultant fees from Abbvie, BMS, Galapagos, Johnson & Johnson, Lilly, Pfizer, Takeda, and Tillotts. P.A. has participated in planning educational meetings for Takeda, is a shareholder in Orion Pharma, and has received lecture fees from Celltrion. K.S. has received speaker and consultant fees from Abbvie, BMS, Janssen, Pfizer, Takeda, and Tillotts Pharma. T.S. has received speaker fees from Abbvie, Celltrion, Johnson & Johnson, Lilly, and Takeda, as well as consultation fees from Abbvie, BMS, Johnson & Johnson, Pfizer, and Takeda and a research grant from Johnson & Johnson. S.K. and E.L. have no conflicts of interest to declare. J.R. has received grant from the Mary and Georg C. Ehrnrooth Foundation.
